Gilder Gagnon Howe & Co. LLC Sells 409,532 Shares of DexCom, Inc. (NASDAQ:DXCM)
Gilder Gagnon Howe & Co. LLC cut its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 90.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 43,423 shares of the medical device company’s stock after selling 409,532 shares during the period. Gilder Gagnon Howe & Co. LLC’s holdings in DexCom were worth $3,176,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in DXCM. Dimensional Fund Advisors LP raised its position in DexCom by 4.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 110,292 shares of the medical device company’s stock worth $6,586,000 after buying an additional 4,682 shares in the last quarter. Teachers Advisors LLC raised its position in DexCom by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 184,560 shares of the medical device company’s stock worth $11,018,000 after buying an additional 7,050 shares during the period. Chevy Chase Trust Holdings Inc. purchased a new position in DexCom during the first quarter worth approximately $3,600,000. Capstone Asset Management Co. purchased a new position in DexCom during the first quarter worth approximately $213,000. Finally, Bremer Trust National Association purchased a new position in DexCom during the first quarter worth approximately $302,000.
DexCom, Inc. (NASDAQ DXCM) opened at 71.54 on Thursday. The firm has a 50-day moving average of $71.63 and a 200 day moving average of $75.29. DexCom, Inc. has a 52-week low of $57.68 and a 52-week high of $96.38. The company’s market capitalization is $6.19 billion.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.07. The company had revenue of $170.60 million during the quarter, compared to analysts’ expectations of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The firm’s revenue for the quarter was up 24.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.24) earnings per share. Equities analysts predict that DexCom, Inc. will post ($0.77) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Gilder Gagnon Howe & Co. LLC Sells 409,532 Shares of DexCom, Inc. (NASDAQ:DXCM)” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/gilder-gagnon-howe-co-llc-sells-409532-shares-of-dexcom-inc-nasdaqdxcm/1468068.html.
A number of research analysts have recently commented on DXCM shares. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of DexCom in a research report on Thursday, April 13th. Cowen and Company reiterated an “outperform” rating and issued a $90.00 target price on shares of DexCom in a research report on Tuesday, April 18th. B. Riley reiterated a “buy” rating and issued a $95.00 target price on shares of DexCom in a research report on Thursday, April 27th. William Blair reiterated an “outperform” rating on shares of DexCom in a research report on Thursday, April 27th. Finally, BTIG Research lowered shares of DexCom from a “buy” rating to a “neutral” rating in a research report on Wednesday, May 3rd. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and fifteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $87.00.
In related news, EVP Steven Robert Pacelli sold 1,450 shares of the company’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $69.47, for a total value of $100,731.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Kevin R. Sayer sold 8,649 shares of the company’s stock in a transaction dated Wednesday, May 17th. The shares were sold at an average price of $68.39, for a total transaction of $591,505.11. Following the completion of the sale, the chief executive officer now directly owns 347,329 shares of the company’s stock, valued at approximately $23,753,830.31. The disclosure for this sale can be found here. Insiders sold 33,131 shares of company stock valued at $2,318,443 over the last quarter. Company insiders own 1.70% of the company’s stock.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.